ABSTRACT NUMBER: ESOC2026A939 EARLY ADJUVANT TIROFIBAN AFTER ENDOVASCULAR THROMBECTOMY: A REAL-WORLD, PROPENSITY-MATCHED ANALYSIS FROM THE TAIWAN TREAT-AIS REGISTRY

Kuo-Cheng Chang, Nien-Chen Liao, Po-Lin Chen · 2026

Read ABSTRACT NUMBER: ESOC2026A939 EARLY ADJUVANT TIROFIBAN AFTER ENDOVASCULAR THROMBECTOMY: A REAL-WORLD, PROPENSITY-MATCHED ANALYSIS FROM THE TAIWAN TREAT-AIS REGISTRY by Kuo-Cheng Chang, Nien-Chen Liao, Po-Lin Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146025.txt.

Description

Kuo-Cheng Chang, Nien-Chen Liao, and Po-Lin Chen report a 2026 conference study on stroke care in Taiwan. The question is whether a clot-blocking drug, tirofiban, given within a day after a thrombectomy helps patients recover. Thrombectomy pulls a clot from a brain artery, but debate over the added drug has continued.

Using a nationwide registry, the team matched two hundred forty-five treated patients with nine hundred eighty untreated ones of like age, sex, and stroke severity. The treated group reached far higher rates of living on their own at ninety days, and fewer died. Rates of brain bleeding did not rise. The authors read this as support for early use of the drug in picked patients.

Catalog record

CREATORKuo-Cheng Chang, Nien-Chen Liao, Po-Lin Chen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13146025

Browse the full library · About the Tower of Babel